BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 04, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HPV-SLP: Phase II started

ISA began an open-label, U.S. Phase II trial to evaluate 100 ug subcutaneous ISA101 every 3-4 weeks for up to 3 doses plus Opdivo nivolumab every 2 weeks...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >